476 related articles for article (PubMed ID: 25125976)
21. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Xia QK; Gao Y; Zhong NS;
COPD; 2013 Apr; 10(2):164-71. PubMed ID: 23061828
[TBL] [Abstract][Full Text] [Related]
22. The role for N-acetylcysteine in the management of COPD.
Dekhuijzen PN; van Beurden WJ
Int J Chron Obstruct Pulmon Dis; 2006; 1(2):99-106. PubMed ID: 18046886
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease.
Biswas S; Hwang JW; Kirkham PA; Rahman I
Curr Med Chem; 2013; 20(12):1496-530. PubMed ID: 22963552
[TBL] [Abstract][Full Text] [Related]
24. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
[TBL] [Abstract][Full Text] [Related]
25. Role of N-acetylcysteine in the management of COPD.
Sadowska AM; Verbraecken J; Darquennes K; De Backer WA
Int J Chron Obstruct Pulmon Dis; 2006; 1(4):425-34. PubMed ID: 18044098
[TBL] [Abstract][Full Text] [Related]
26. N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation.
Calzetta L; Rogliani P; Facciolo F; Rinaldi B; Cazzola M; Matera MG
Biomed Pharmacother; 2018 Jul; 103():1-8. PubMed ID: 29635121
[TBL] [Abstract][Full Text] [Related]
27. Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Shen Y; Cai W; Lei S; Zhang Z
COPD; 2014 Jun; 11(3):351-8. PubMed ID: 24378052
[TBL] [Abstract][Full Text] [Related]
28. [Acetylcysteine in the treatment of severe COPD].
Dekhuijzen PN
Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1222-6. PubMed ID: 16796172
[TBL] [Abstract][Full Text] [Related]
29. New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease.
Brassington K; Selemidis S; Bozinovski S; Vlahos R
Clin Sci (Lond); 2019 Apr; 133(7):885-904. PubMed ID: 30979844
[TBL] [Abstract][Full Text] [Related]
30. Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease.
Calzetta L; Matera MG; Rogliani P; Cazzola M
Expert Rev Respir Med; 2018 Aug; 12(8):693-708. PubMed ID: 29972340
[TBL] [Abstract][Full Text] [Related]
31. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease.
Dekhuijzen PN
Eur Respir J; 2004 Apr; 23(4):629-36. PubMed ID: 15083766
[TBL] [Abstract][Full Text] [Related]
32. N-acetylcysteine in patients with COPD exacerbations associated with increased sputum.
Ayfer Aytemur Z; Baysak A; Ozdemir O; Köse T; Sayiner A
Wien Klin Wochenschr; 2015 Apr; 127(7-8):256-61. PubMed ID: 25595117
[TBL] [Abstract][Full Text] [Related]
33. Statins in the treatment of COPD and asthma-where do we stand?
So JY; Dhungana S; Beros JJ; Criner GJ
Curr Opin Pharmacol; 2018 Jun; 40():26-33. PubMed ID: 29334676
[TBL] [Abstract][Full Text] [Related]
34. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis.
Schermer T; Chavannes N; Dekhuijzen R; Wouters E; Muris J; Akkermans R; van Schayck O; van Weel C
Respir Med; 2009 Apr; 103(4):542-51. PubMed ID: 19138505
[TBL] [Abstract][Full Text] [Related]
35. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study.
Stav D; Raz M
Chest; 2009 Aug; 136(2):381-386. PubMed ID: 19447919
[TBL] [Abstract][Full Text] [Related]
36. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial.
Johnson K; McEvoy CE; Naqvi S; Wendt C; Reilkoff RA; Kunisaki KM; Wetherbee EE; Nelson D; Tirouvanziam R; Niewoehner DE
Int J Chron Obstruct Pulmon Dis; 2016; 11():799-807. PubMed ID: 27143871
[TBL] [Abstract][Full Text] [Related]
37. Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation.
Calverley PM; Page C; Dal Negro RW; Fontana G; Cazzola M; Cicero AF; Pozzi E; Wedzicha JA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2733-2744. PubMed ID: 31819405
[TBL] [Abstract][Full Text] [Related]
38. The efficacy of
Huang C; Kuo S; Lin L; Yang Y
Ther Adv Respir Dis; 2023; 17():17534666231158563. PubMed ID: 36927162
[TBL] [Abstract][Full Text] [Related]
39. Oral N-acetylcysteine attenuates pulmonary emphysema and alveolar septal cell apoptosis in smoking-induced COPD in rats.
Cai S; Chen P; Zhang C; Chen JB; Wu J
Respirology; 2009 Apr; 14(3):354-9. PubMed ID: 19341424
[TBL] [Abstract][Full Text] [Related]
40. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease.
Sutherland ER; Crapo JD; Bowler RP
COPD; 2006 Dec; 3(4):195-202. PubMed ID: 17361500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
